Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Non-Deal Roadshow (September 2021)
35 slides from Amoeba Sa's roadshow presentation, September 2021
Slide 1: Disclaimer
When receiving this presentation or participating in this meeting, you acknowledge having taken note of the following restrictions. The present document and the information contained in the presentation are strictly confidential. This document cannot be copied, reproduced, distributed, published or
Slide 2: Agenda
PLANT PROTECTION Plant protection, a problem of public heath. Q A DISRUPTIVE TECHNOLOGY Amoéba, a research technology plateform AMOEBA . About us . Our vision o—___-e NEXT STEPS . Board of Directors Current situation and regulatory focus. FINANCIAL ASPECTS Succesful IPO and fundraising, Company's sh
Slide 3: Amoeba Company
®QOo0deé AMOEBA COMPANY OUR VISION AND MISSION A DISRUPTIVE TECHNOLOGY AMOEBA KEY FIGURES BOARD OF DIRECTORS
Slide 4: A wind of change in treating crucial resources
A wind of change is blowing on the way to treat our crucial resources (water, food and air). Amoéba is a key actor of this groundswell. By combining our proprietary technology, an amoeba, and our scientific knowledge on microbiology, amoéba contributes to enlarge the offer for safer products.
Slide 5: Amoeba used alive as biocide or lysed as biocontrol agent
Used alive as a Used lysed as a biocide biocontrol agent •100% biological • Non genetically modified • Eats bacteria, including Legionella, amoebas in water, Fungi, etc. • Wide spectrum biofungicide
Slide 6: Intellectual property and know-how
A patented technology and accumulated know-how as a global approach for a worldwide commercialization INTELLECTUAL KNOW-HOW PROPERTY Registered patents : • Proprietary culture medium ; • Legionnella ; • Industrial process ; • Listeria ; • Continuous production ; • Pseudomonas ; • Etc. • Naegleria fo
Slide 7: Amoeba key figures
25 19 1 € 25M R&D 19 employees in 1 production line expenditure & France (200m3) in France investment since 2010
Slide 8: Board of Directors
Bernard AMBOLET Valérie FILIATRE Administrator Administrator & (Expert in agriculture Chief Financial Officer & Biocontrol ) Philippe DUJARDIN Administrator Fabrice (Expert in finance PLASSON and strategy) CEO Pierre MORGON Claudine VERMOT- Administrator DESROCHES (Expert in life and health sciences
Slide 9: Financial Aspects
FINANCIAL ASPECTS ~ST N ~ @ STOCK MARKET “XN XN / 7___\ yf FINANCIAL SITUATION Po 7 Cee =- _~ _—_-—
Slide 10: A successful IPO and fundraising
A SUCCESSFUL IPO & FUNDRAISING € 13.2M Raised during the IPO in July 2015 € 29 market capitalisation € 14.7M Raised in 2016 with private placement IPO : €44.5 market cap. € 5M Financing agreement with the European Investment Bank (EIB) in 2017 € 6M OCAPI with Nice & € 1.63 Green in 2018 € 6M OCAPI w
Slide 11: Share analysis, liquidity and shareholding
SHARE ANALYSIS +134% Of growth in 2020 LIQUIDITY ANALYSIS SHARE HOLDING More than 92% 7% 1% FREE FLOATING CEO VP 15 % Is the percentage of the rolling average volume
Slide 12: Burn rate, EIB debt, equity and revenue
B U R N R AT E EIB DEBT 2019 2020 2019 2020 € 333K € 410K € 7,2M € 7,9M EQUITY REVENUE 2019 2020 2019 2020 € 4,2M € 2,0M No revenue No revenue
Slide 13: Amoeba, a research technology platform
cule AMOEBA, A RESEARCH eal) TECHNOLOGY PLATFORM PREVISIONNAL CALENDAR
Slide 14: NOE production line
The NOE production line is an industrial unit that produces Willaertia magna in large quantities for commercial use. 2x500L biorectors 11 x tanks 1000L 8M€ 8% RED BIOTECH GREEN BIOTECH SKIN DESINFECTANT : • Wound care • Cosmetology BIOCONTROL AGENT : BLUE • • BIOTECHGrape downy mildew Potato late bl
Slide 15: Green, red and white biotech applications
Our core technology and first in class scientific knowledege on amoeba enables us to consider multiple applications GREEN BIOTECH RED BIOTECH BIOCONTROL AGENT : SKIN DESINFECTANT : Wide spectrum on key • Wound care markets (vines, vegetables, • Cosmetology cereals, soybeans…) WHITE BIOTECH BIOCIDE :
Slide 16: Marketing conditioned on prior marketing authorization
The marketing of our products is conditioned on obtaining prior marketing authorization
Slide 17: Biocide regulatory timeline
BIOCIDE WILLAERTIA MAGNA C2c MAKY ALIVE AND RELATED PRODUCTS EU: Decision to approve EU: Provisional Marketing EU : Submission of a the Active Substance (EU Authorization Decisions (Member EU : Pre-submission new application for Commission) States or EU Commission) meeting with the the Biocidal Acti
Slide 18: Biocontrol regulatory timeline
BIOCONTROL WILLAERTIA MAGNA C2c MAKY LYSAT AND RELATED PRODUCTS EU: Decision to approve the EU : Submission of the Active Active Substance (European Substance file to the Commission) EU : Pre-submission evaluating authority (Austria) meeting with the EU: Evaluation Report EU : Authorization decision
Slide 19: Biocontrol
BIOCONTROL © MAIN PROBLEM © MARKETS TARGETED BY AMOEBA ‘oe VALUE PROPOSITION S COMPETITION MANUFACTURING BUSINESS MODEL fe] COMMERCIALISATION & 7 MARKETING STRATEGY
Slide 20: Pain: issues in plant protection
PAIN : Environmental Limited biocontrol solutions, old pesticides Governments and people seek for impact 78% are increasingly banned alternative « greener » solutions but reduction of insects (EU), even copper is equally effective. from 1989 to 2013 under regulatory pressure (EU) Public health issue
Slide 21: Target crops and markets
VINE Diseases : Powdery & POTATOES Disease : Late Blight Downy mildew EU : €250 M EU : €500 M US : €100 M US : €150 M Field Tests : 3 years Field Tests : 3 years WHEAT SOYBEAN Diseases : Rusts, Disease : Asian rust Septoria Fusarium BRAZIL : €2,100 M EU : €2 000 M Field Tests : 1 year US : €400 M Fi
Slide 22: Unique dual mode of action
Unique dual mode of action A wide spectrum of action in plant protection More effective than current biocontrol agents No hazard for humans and for the environment. Good complementarity with conventional fungicides
Slide 23: Competitive advantages
COMPETITIVE ADVANTAGES •Our product has outstanding performance compared to current biocontrol alternatives (downy mildew of grapes and vegetables) •Only a few biocontrol products are being marketed for grapevine protection against both downy mildew AND powdery mildew. •Today, there is no natural so
Slide 24: Revenue model
REVENUE MODEL REVENUE STREAM Partnership agreements with Sales of our product to partners. agrochemical & biocontrol companies to formulate the active substance in plant products and sell them in targeted countries (according to partner’s size).
Slide 25: Strategy approach
AMOÉBA STRATEGY APPROACH R&D, IP management Manufactures the final •Cooperatives & farmers will be reached through product the distribution chain of the partner companies. •Go-to-market target plant diseases are downy PARTNER COMPANIES mildews and late blight on grapevines, (agro-chemical distributo
Slide 26: A disruptive technology: Biomeba
A DISRUPTIVE TECHNOLOGY A MARKET DOMINATED BY CHEMISTRY SO) APPLICATIONS’ OVERVIEW ®@ BIOMEBA ) AMOEBA'S PRODUCT OFFER OUR EXPERIENCE A COMPETITIVE SOLUTION
Slide 27: Water treatment market and chemical biocides
• The water treatment market is subject to regulations to prevent microbial health risks. • 3 main chemicals biocides share the European water treatment market Chloride Early 1900 CHEMICAL BIOCIDES ARE : Bromide Early 1900 Underperforming Dangerous Isothiazolone 1974 Expensive Don’t respect directiv
Slide 28: Water treatment applications
Nuclear power plant CT Air Industrial CT: € 1.7 billion Cooling Towers (CT) Cooling Towers (CT) Water from cooling towers Water from cooling circuits Veterinary industry Drinking water for animals Pulp and paper industry Drinking water network Water for paper treatment Food and agriculture Industry
Slide 29: Biomeba, alternative to chemical biocides in cooling towers
is the alternative to chemical biocides in Cooling Towers Industrial CT: € 1.7 billion Cooling Towers (CT) Water from cooling circuits • A natural amoeba, isolated from thermal waters in Aix-les-Bains • The only biocide without class of hazards to human health and the environment* • Effective: on mi
Slide 30: Biomeba versus chemical treatments
BIOMEBA: a powerful biocide destroying free microorganisms & their reservoir VS EFFICIENT ON WATER AND BIOFILMS INEFFICIENT ON BIOFILMS BIOMEBA’s biological treatment Chemical treatments cover 5% covers 95% of the bacterial risk of the bacterial risk* 10L or 20L *Dalkia Study - June 2008: 99.5% of L
Slide 31: Field trials by business sector
10 cumulated years of conclusive field trials on 27 end users’ sites. BUSINESS SECTOR : Commercial buildings : 6 tests Food industry : 4 tests Airport : 2 tests Automotive : 1 test Heavy industry : 4 tests Pharmaceutical : 2 tests Chemistry : 5 tests Electronic : 1 test Plastic industry : 1 test
Slide 32: Overall cost of use
Using Amoéba’s biocide means savings at different levels Biocide Anti-scaling/ anti-corrosion Biodispersant Water consumption Tax on chemical discharge Corrosion Transport and storage volume Overall cost of use
Slide 33: Regulatory focus
A DISRUPTIVE TECHNOLOGY REGULATORY FOCUS ea a) 9 6) \|E8ee9euedd AMOEBA’S ACTUALITIES OOOOOOO OOOOOO
Slide 34: Regulatory status for biocontrol and biocide
BIOCONTROL BIOCIDE EUROPE EUROPE Dossier submitted May 2020. Next Dossier submitted Aug step: draft assessment report, 2019. Next step: draft expected end of 2021. assessment report, expected end of 2021. USA Dossier submitted Sep 2020. Next USA step: decision by the authority Dossier resubmitted Ma
Slide 35: Amoeba's actualities
•New website including Plant Protection activity. •New financing line with Nice & Green for €24 M over 18 months-period. •A new Board member (Philippe Dujardin) •Higher production margin due to industrial process optimization